This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Advanced Cancers
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

Primary Objective: - To determine a recommended Phase 2 dose of LY2275796 that may be safely administered to patients with advanced cancer, with prospects for therapeutic biologic effects. This will require simultaneous: - monitoring of toxicities & determination of maximal tolerated dose (MTD) - detecting eIF-4E target inhibition in tumor - pharmacokinetic measurements Secondary Objectives: - To estimate pharmacokinetic parameters of LY2275796 and explore pharmacokinetic/pharmacodynamic relationships - To document any antitumor activity observed with LY2275796

Provided treatments

  • Drug: LY2275796
Tris trial is registered with FDA with number: NCT00903708. The sponsor of the trial is M.D. Anderson Cancer Center and it is looking for 24 volunteers for the current phase.
Official trial title:
A Phase I Dose-Escalation, Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous LY2275796 in Patients With Advanced Cancer